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The present study. In this issue of the Journal, Takeda
and his colleagues (1) describe their studies comparing the
accuracy and sensitivity in myocardial infarct detection of
technetium (Tc)-99m pyrophosphate and indium-Ill antimy-
osin imaging in dogs with temporary and permanent coro-
nary artery occlusions. The myocardial tissue localization of
Tc-99m pyrophosphate and antimyosin antibody was com-
pared in 11 dogs 24 to 68 h after left anterior descending
coronary artery occlusion. In four dogs the coronary occlu-
sion was permanent, and in seven it was temporary and
followed by reperfusion. Tc-99m pyrophosphate and antimy-
osin antibody concentrations were determined in serial 2 to
3 mm wide endocardial and epicardial samples and multiple
short-axis left ventricular slices within the infarct zones. The
number of samples with increased antimyosin antibody was
not significantly different from that with increased Tc-99m
pyrophosphate uptake both in dogs with permanent and in
dogs with temporary coronary artery occlusion. The inten-
sity of uptake of Tc-99m pyrophosphate exceeded that of the
antimyosin antibody, especially in the border zones of
reperfused infarcts. Moreover, the area of myocardium with
moderate to marked increases in tracer uptake (2:2 times
normal) was larger with Tc-99m pyrophosphate than with
antimyosin antibody (p < 0.001). A specific zone of abnor-
mal Tc-99m pyrophosphate, but without increased antimyo-
sin antibody uptake, was not identified in these studies.
Histologic evidence of myocardial necrosis was found in
virtually every myocardial sample with increased antimyosin
antibody, Tc-99m pyrophosphate, or both.
The investigators (1) conclude that Tc-99m pyrophos-
phate and antimyosin antibody should represent equally
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good markers for the detection of irreversible myocardial
injury with and without myocardial reperfusion after myo-
cardial infarction. They further suggest that the larger scin-
tigraphic estimates of infarct size with Tc-99m pyrophos-
phate found in some previous studies were most likely due to
greater uptake of Tc-99m pyrophosphate in necrotic myo-
cytes, especially those located at the infarct boundaries
rather than increased uptake of pyrophosphate in injured
viable myocardial tissue.
Previous studies. This study should help to end any
continuing controversy concerning whether Tc-99m pyro-
phosphate or antimyosin antibody is a markedly superior
method for detecting or sizing myocardial infarcts when the
proper methods and instrumentation are used. Previous
studies (2-18) have demonstrated that both imaging tech-
niques have good sensitivity in detecting myocardial necro-
sis in experimental animal models and in patients. However,
because Tc-99m pyrophosphate uptake has been found in
clinical settings where myocardial necrosis was not always
evident, including in some patients with unstable angina,
cardiomyopathy and heart failure and in some patients with
persistently abnormal uptake after myocardial infarction
(7,8,18,19), it has been suggested that pyrophosphate uptake
may occur in reversibly injured myocardial tissue. Detailed
research studies conducted by several groups (13,15-17)
have demonstrated that antimyosin antibody uptake occurs
in irreversibly injured myocardial tissue and that extensive
disruption of membrane integrity is required for it to con-
centrate in increased amounts. A few comparative studies
(14) in which the extent of Tc-99m pyrophosphate and
antimyosin antibody uptake were measured in animal mod-
els and patients with infarction have suggested that the area
of pyrophosphate uptake is greater than for the antimyosin
antibody, thus also suggesting that pyrophosphate uptake
may occur in reversibly injured cells in some circumstances.
On the other hand, extensive animal and clinical studies
(3-12) have shown that Tc-99m pyrophosphate uptake oc-
curs predominantly in irreversibly injured tissue. These
previous studies have included detailed morphologic com-
parisons at light and electron microscopic levels (5-8),
comparisons of Tc-99m pyrophosphate uptake with abnor-
malities in myocardial mitochondrial function after ex-
perimental coronary artery occlusion (10), comparisons of
pyrophosphate uptake with triphenyltetrazolium chloride
staining of experimental infarcts (20) and detailed morpho-
logic measurements of infarct size versus the extent of
pyrophosphate uptake in experimental animal models with
myocardial infarction (11,12).
Estimation of infarct size after reperfusion. Theoretically,
experimental or clinical circumstances where transient but
marked increases in cytosolic calcium concentration occur
in reversibly injured myocytes might lead to increased
pyrophosphate uptake (5,6). This may occur if Tc-99m
pyrophosphate myocardial imaging is performed immedi-
ately after reperfusion. Indeed, differences in infarct size
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with pyrophosphate imaging and single photon emISSIOn
computed tomography (SPECT) have been shown (12) in
canine models with temporary coronary artery occlusion
followed by reperfusion depending on whether the pyro-
phosphate is injected 10 to 15 or 90 min after reperfusion. If
the pyrophosphate is injected immediately with reperfusion,
there is an overestimation of infarct size in experimental
animal studies. However, if the injection is made after 90
min of reperfusion, there is an accurate estimate of infarct
size by pyrophosphate and SPECT imaging (12). These
studies have led to the recommendation that Tc-99m pyro-
phosphate be injected no sooner than 90 min after reperfu-
sion. The overestimation of infarct size associated with
immediate injection of pyrophosphate after reperfusion is
most likely caused by transient uptake of pyrophosphate in
selected cells populations with cytosolic calcium overload
and reversible myocardial injury (12). In the study ofTakeda
et al. (1), the injection of Tc-99m pyrophosphate was accom-
plished 2 h after the start of reperfusion (0; thus, one might
anticipate similar findings to those reported in the earlier
studies mentioned previously (12).
Indium-Ill antimyosin antibody versus Tc·99m pyrophos-
phate imaging. As more experience has been gained with
indium-Ill antimyosin antibody imaging, it has become
clear that there are several similarities with Tc-99m pyro-
phosphate imaging (21). First, a certain percentage of pa-
tients with dilated cardiomyopathy have abnormal indium-
III antimyosin antibody images in the absence of clinically
evident myocardial infarction (21). Second, persistent abnor-
malities in indium-Ill antimyosin antibody scintigrams oc-
cur in some patients after myocardial infarction (Haber E
and Berger H, personal communication, 1990), just as had
been described previously for Tc-99m pyrophosphate (7).
The persistently abnormal Tc-99m pyrophosphate scinti-
grams in patients after infarction have often served as
markers of a complicated future course. Deterioration in
ventricular function occurs in many of these patients. sug-
gesting that persistently abnormal Tc-99m pyrophosphate
scintigrams may be the result of ongoing chronic cellular
injury and necrosis (7,22.23).
From the data available, we agree with Takeda et al. (1)
that both Tc-99m pyrophosphate and In-Ill antimyosin
antibody imaging should provide equally acceptable, but
alternative, means to detect irreversible myocardial injury
and myocardial infarction when the issue is in doubt clini-
cally. Similarly, both techniques should provide a good
means to estimate the extent of myocardial infarction when
proper imaging instrumentation allowing three-dimensional
reconstruction of the infarct is used, attention to the ideal
imaging characteristics for both tracers is observed and the
images are interpreted by observers experienced in the use
of the respective tracers.
For those who have worked to develop these imaging
methods and have been frustrated previously by conflicting
results and controversy, it is rewarding to have further
confirmation that both of these imaging techniques are
valuable in the noninvasive detection of acute myocardial
necrosis.
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